Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Madison Chacon"'
Autor:
Michelle Boisvert, Ashwyn A Perera, Alexandra L Condurat, John Jeang, Jessica W Tsai, Dana Novikov, Kevin Zhou, Madison Chacon, Jeromy DiGiacomo, Rushil Kumbhani, Dayle Wang, Michael D Taylor, Jordan R Hansford, Louise Ludlow, Nada Jabado, Keith L Ligon, Rameen Beroukhim, Pratiti Bandopadhayay, David T W Jones
Publikováno v:
Neuro-Oncology. 24:i101-i102
Pediatric low-grade gliomas (pLGGs) are the most frequent brain tumors in children and comprise a heterogeneous group of tumors with different locations, histologic subtypes, ages at presentation, and clinical behavior. Tumors frequently respond to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb5c43c9c5cee98c931dcc8151a05cdf
https://doi.org/10.1093/neuonc/noac079.369
https://doi.org/10.1093/neuonc/noac079.369
Autor:
Leslie Lupien, Adam Boynton, Madison Chacon, Rushil Kumbhani, Gabrielle Gionet, Amy Goodale, David Root, Hasmik Keshishian, Margaret Robinson, Steven Carr, Pratiti Bandopadhayay
Publikováno v:
Neuro-Oncology. 24:i123-i123
MYC-driven medulloblastomas are a particularly devastating group of pediatric brain tumors that exhibit resistance and continued progression despite standard of care treatments. Our preclinical work identified BET-bromodomain inhibitors as a potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc9c6f9df5d83e7af6232ff75f570ef9
https://doi.org/10.1093/neuonc/noac079.447
https://doi.org/10.1093/neuonc/noac079.447
Autor:
Adam Boynton, Leslie Lupien, Rushil Kumbhani, Gabrielle Gionet, Madison Chacon, Amy Goodale, David Root, Hasmik Keshishian, Margaret Robinson, Steven Carr, Pratiti Bandopadhayay
Publikováno v:
Neuro-Oncology. 24:i126-i126
BET-bromodomain inhibition (BETi) is a promising therapeutic strategy to target MYC-driven cancers, including Group 3 medulloblastoma, a deadly childhood brain tumor. We have shown that BET inhibitors exhibit preclinical efficacy against MYC¬-amplif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::591a3344becc33109b42b430a229a90f
https://doi.org/10.1093/neuonc/noac079.459
https://doi.org/10.1093/neuonc/noac079.459
Autor:
Leslie Lupien, Veronica Rendo, Eric Morin, Nicholas Khuu, Jeromy DiGiacomo, Prasidda Khadka, Madison Chacon, Sophie Lu, Kristine Pelton, Lara Elcavage, Jaldeep Langhnoja, Keith Ligon, Rameen Beroukhim, Timothy Phoenix, Pratiti Bandopadhayay
Publikováno v:
Neuro-Oncology. 24:i31-i31
TP53 is the most frequently mutated tumor suppressor with somatic alterations found in approximately 50% of all human cancers. In the remaining TP53 wild-type (WT) tumors, functional inactivation of the p53 pathway may be achieved through a variety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09d35f117b0a17b5cb7c195f2c549ce5
https://doi.org/10.1093/neuonc/noac079.111
https://doi.org/10.1093/neuonc/noac079.111